Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncoscience AG

www.oncoscienceag.com

Latest From Oncoscience AG

EU application for nimotuzumab for pediatric glioma withdrawn

Oncoscience AG has withdrawn its application to the EMEAfor marketing authorisation of the EGFR-targeted drug nimotuzumab for the treatment of paediatric glioma (brain cancer), saying that it was not able to adequately address the concerns of the CHMP regarding the quality and efficacy of the medicine within the required time schedule.

Cancer Approvals

YM BioSciences plans pivotal NSCLC trial for nimotuzumab

YM BioSciences' experimental EGFR-targeted humanised monoclonal antibody drug nimotuzumab (YMB1000-015) will not progress to a pivotal trial in colorectal cancer at this time, but the Canadian company instead proposes to advance it into two other pivotal trials this year, including one in non-small cell lung cancer (NSCLC), which it believes could result in faster marketing approval.

Gastrointestinal Cardiovascular

The Lure of Late-Stage Device Investing

In 2006, the number of late-stage private equity deals in the medical device sector is up significantly from 2005. At the IN3 East medtech conference in October, a lively panel of venture capital investors from Galen Partners, 3i, Matignon Technologies and OrbiMed Advisors discussed why this is so, and the risks, benefits and models for late-stage investing.
Medical Device Business Strategies

Recent Dealmaking (12/2003)

Summarizing the month in European dealmaking.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Oncoscience AG
  • Senior Management
  • Ferdinand Bach, CEO
  • Contact Info
  • Oncoscience AG
    Phone: (49) 4103 180 880
    Hafenstraße 32
    Wedel, D-22880
    Germany
UsernamePublicRestriction

Register